{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:15:19Z","timestamp":1787764519518,"version":"build-2784847793"},"reference-count":58,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2022,12,1]]},"abstract":"\n Importance<\/jats:title>\n Cutaneous disease in dermatomyositis has no standardized treatment approach and so presents a challenging task for patients and clinicians.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To study the efficacy and safety of apremilast as an add-on therapy in patients with recalcitrant cutaneous dermatomyositis.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This phase 2a, open-label, single-arm nonrandomized controlled trial was conducted at a single center from June 2018 to June 2021. Participants were 8 patients with recalcitrant cutaneous dermatomyositis, defined by a cutaneous disease activity severity index (CDASI) score greater than 5 despite treatment with steroids, steroid-sparing agents, or both. Data were analyzed from June 2018 to June 2021.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Apremilast 30 mg orally twice daily was added to ongoing treatment regimens.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was the overall response rate (ORR) at 3 months. Key secondary outcomes were the safety and toxicity of apremilast and the durability of response at 6 months. The CDASI, muscle score, dermatology life quality index (DLQI), and depression assessments were performed at baseline and regularly until month 7. Skin biopsies were performed at baseline and 3 months after apremilast (defined as 3 months into active apremilast therapy) and tested for gene expression profiling and immunohistochemical stains. Adverse events were assessed using the Common Terminology Criteria for Adverse Events version 5.0.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 8 patients with recalcitrant cutaneous dermatomyositis (all women; mean [SD] age, 54 [15.9] years), a response was found at 3 months after apremilast among 7 patients (ORR, 87.5%). The mean (SD) decrease in CDASI was 12.9 (6.3) points at 3 months (\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Apremilast was well tolerated, with no grade 3 or higher adverse events. Sequencing of RNA was performed on skin biopsies taken from 7 patients at baseline and at 3 months after therapy. Appropriate negative (ie, no primary antibody) and positive (ie, tonsil and spleen) controls were stained in parallel with each set of slides studied. Of 39\u202f076 expressed genes, there were 195 whose expression changed 2-fold or more at\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.01 (123 downregulated and 72 upregulated genes). Gene set enrichment analysis identified 13 pathways in which apremilast was associated with downregulated expression, notably signal transducers and activators of transcription 1 (STAT1), STAT3, interleukin 4 (IL-4), IL-6, IL-12, IL-23, interferon \u03b3 (IFN\u03b3), and tumor necrosis factor \u03b1 (TNF\u03b1) pathways. In immunohistochemical staining, there was a mean (SD) decrease in phosphorylation levels STAT1 (22.3% [28.3%] positive cells) and STAT3 (13.4% [11.6%] positive cells) at the protein level, a downstream signaling pathway for the downregulated cytokines.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n These findings suggest that apremilast was a safe and efficacious add-on treatment in recalcitrant dermatomyositis, with an overall response rate of 87.5% and associations with downregulation of multiple inflammatory pathways.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT03529955<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2022.3917","type":"journal-article","created":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T11:01:06Z","timestamp":1664967666000},"page":"1357","source":"Crossref","is-referenced-by-count":26,"title":["Apremilast in Recalcitrant Cutaneous Dermatomyositis"],"prefix":"10.1001","volume":"158","author":[{"given":"Carole","family":"Bitar","sequence":"first","affiliation":[{"name":"Department of Dermatology, Tulane University School of Medicine, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thien","family":"Ninh","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Brag","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soraya","family":"Foutouhi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, Davis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Radosta","sequence":"additional","affiliation":[{"name":"Deming Department of Medicine, Tulane University, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade","family":"Meyers","sequence":"additional","affiliation":[{"name":"School of Medicine, Tulane University, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody","family":"Baddoo","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Tulane University, New Orleans, Louisiana"},{"name":"Tulane Cancer Center, Tulane University, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delong","family":"Liu","sequence":"additional","affiliation":[{"name":"National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Stumpf","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tulane University School of Medicine, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W.","family":"Harms","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakhle S.","family":"Saba","sequence":"additional","affiliation":[{"name":"Section of Hematology and Medical Oncology, Deming Department of Medicine, Tulane University, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Boh","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tulane University School of Medicine, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9197","key":"doi220052r1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(99)05157-0","article-title":"Dermatomyositis.","volume":"355","author":"Callen","year":"2000","journal-title":"Lancet"},{"issue":"1","key":"doi220052r2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamadermatol.2017.3758","article-title":"Factors associated with clinical remission of skin disease in dermatomyositis.","volume":"154","author":"Wolstencroft","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"2","key":"doi220052r3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jaad.2019.05.105","article-title":"Dermatomyositis: diagnosis and treatment.","volume":"82","author":"Waldman","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi220052r4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"doi220052r5","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/bjd.2015.173.issue-6","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).","volume":"173","author":"Paul","year":"2015","journal-title":"Br J Dermatol"},{"issue":"20","key":"doi220052r6","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1056\/NEJMoa1816594","article-title":"Trial of apremilast for oral ulcers in Beh\u00e7et\u2019s syndrome.","volume":"381","author":"Hatemi","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"doi220052r7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/09546634.2019.1589641","article-title":"Off-label studies on apremilast in dermatology: a review.","volume":"31","author":"Maloney","year":"2020","journal-title":"J Dermatolog Treat"},{"issue":"10","key":"doi220052r8","first-page":"1224","article-title":"Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study.","volume":"11","author":"De Souza","year":"2012","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"doi220052r9","doi-asserted-by":"publisher","DOI":"10.1111\/dth.v33.6","article-title":"Apremilast in dermatology: a review of literature.","volume":"33","author":"Nassim","year":"2020","journal-title":"Dermatol Ther"},{"issue":"28","key":"doi220052r10","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.2174\/0929867324666170530093902","article-title":"Phosphodiesterase 4 inhibitors in immune-mediated diseases: mode of action, clinical applications, current and future perspectives.","volume":"24","author":"Sakkas","year":"2017","journal-title":"Curr Med Chem"},{"issue":"2","key":"doi220052r11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jdcr.2018.11.019","article-title":"Apremilast as a potential treatment for moderate to severe dermatomyositis: a retrospective study of 3 patients.","volume":"5","author":"Bitar","year":"2019","journal-title":"JAAD Case Rep"},{"key":"doi220052r12","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000999","article-title":"Refractory cutaneous dermatomyositis with severe scalp pruritus responsive to apremilast.","author":"Charlton","year":"2019","journal-title":"J Clin Rheumatol"},{"key":"doi220052r13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jpeds.2017.01.046","article-title":"Race, income, and disease outcomes in juvenile dermatomyositis.","volume":"184","author":"Phillippi","year":"2017","journal-title":"J Pediatr"},{"issue":"3","key":"doi220052r14","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0733-8635(02)00021-9","article-title":"Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects.","volume":"20","author":"Sontheimer","year":"2002","journal-title":"Dermatol Clin"},{"issue":"2","key":"doi220052r15","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"17","key":"doi220052r16","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3662","article-title":"Intravenous immunoglobulins in a series of 32 rare and recalcitrant immune dermatoses.","volume":"100","author":"Scarpone","year":"2020","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"doi220052r17","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/art.v73.5","article-title":"Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients.","volume":"73","author":"Paik","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"doi220052r18","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.semarthrit.2020.01.002","article-title":"The validity and utility of the Cutaneous Disease Area and Severity Index (CDASI) as a clinical outcome instrument in dermatomyositis: a comprehensive review.","volume":"50","author":"Ahmed","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"doi220052r19","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/bjd.13915","article-title":"Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change.","volume":"173","author":"Anyanwu","year":"2015","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi220052r20","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1182\/blood-2015-11-681460","article-title":"Pathogenic role of B-cell receptor signaling and canonical NF-?B activation in mantle cell lymphoma.","volume":"128","author":"Saba","year":"2016","journal-title":"Blood"},{"issue":"1","key":"doi220052r21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner.","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"issue":"8","key":"doi220052r22","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","article-title":"Strelka2: fast and accurate calling of germline and somatic variants.","volume":"15","author":"Kim","year":"2018","journal-title":"Nat Methods"},{"issue":"5","key":"doi220052r23","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nbt.3519","article-title":"Near-optimal probabilistic RNA-seq quantification.","volume":"34","author":"Bray","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"3","key":"doi220052r24","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/ced.1994.19.issue-3","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use.","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"doi220052r25","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","article-title":"Translating the science of quality of life into practice: W\\what do dermatology life quality index scores mean?","volume":"125","author":"Hongbo","year":"2005","journal-title":"J Invest Dermatol"},{"issue":"10","key":"doi220052r26","doi-asserted-by":"publisher","first-page":"e393","DOI":"10.1111\/jdv.2018.32.issue-10","article-title":"Adverse events associated with apremilast use and withdrawal for psoriasis in a real-world setting.","volume":"32","author":"Lee","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"doi220052r27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.598702","article-title":"Clinical relevance of the anti-inflammatory effects of roflumilast on human bronchus: potentiation by a long-acting beta-2-agonist.","volume":"11","author":"Salvator","year":"2020","journal-title":"Front Pharmacol"},{"issue":"1","key":"doi220052r28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/nan.2005.31.issue-1","article-title":"Expression of the beta chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies.","volume":"31","author":"Civatte","year":"2005","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"4","key":"doi220052r29","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/bjd.v182.4","article-title":"Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis.","volume":"182","author":"Ahmed","year":"2020","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi220052r30","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jaad.2004.12.015","article-title":"Cutaneous symptoms of dermatomyositis significantly impact patients\u2019 quality of life.","volume":"54","author":"Hundley","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"doi220052r31","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.clindermatol.2018.04.003","article-title":"Dermatomyositis: current concepts.","volume":"36","author":"Bogdanov","year":"2018","journal-title":"Clin Dermatol"},{"issue":"6","key":"doi220052r32","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1111\/bjd.2018.179.issue-6","article-title":"The pathogenesis of dermatomyositis.","volume":"179","author":"Thompson","year":"2018","journal-title":"Br J Dermatol"},{"issue":"8","key":"doi220052r33","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1212\/WNL.59.8.1170","article-title":"Molecular profiles of inflammatory myopathies.","volume":"59","author":"Greenberg","year":"2002","journal-title":"Neurology"},{"issue":"5","key":"doi220052r34","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ana.v57:5","article-title":"Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis.","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann Neurol"},{"issue":"11","key":"doi220052r35","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis.","volume":"56","author":"Walsh","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"1","key":"doi220052r36","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000811","article-title":"Distinct interferon signatures stratify inflammatory and dysimmune myopathies.","volume":"5","author":"Rigolet","year":"2019","journal-title":"RMD Open"},{"issue":"6","key":"doi220052r37","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1093\/brain\/awy105","article-title":"JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis.","volume":"141","author":"Ladislau","year":"2018","journal-title":"Brain"},{"issue":"6","key":"doi220052r38","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/art.2019.71.issue-6","article-title":"Muscle Expression of type I and type II interferons is increased in juvenile dermatomyositis and related to clinical and histologic features.","volume":"71","author":"Moneta","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"doi220052r39","doi-asserted-by":"publisher","first-page":"e1193","DOI":"10.1212\/WNL.0000000000008128","article-title":"Identification of distinctive interferon gene signatures in different types of myositis.","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"doi220052r40","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13075-020-02160-9","article-title":"Expression of interferon-regulated genes in juvenile dermatomyositis versus mendelian autoinflammatory interferonopathies.","volume":"22","author":"Kim","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"doi220052r41","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10067-015-3080-1","article-title":"Serum IL8 and mRNA level of CD11b in circulating neutrophils are increased in clinically amyopathic dermatomyositis with active interstitial lung disease.","volume":"35","author":"Zou","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"1","key":"doi220052r42","doi-asserted-by":"publisher","first-page":"5498","DOI":"10.1038\/s41598-018-23539-4","article-title":"Interleukin-23 as a therapeutic target for inflammatory myopathy.","volume":"8","author":"Umezawa","year":"2018","journal-title":"Sci Rep"},{"issue":"11","key":"doi220052r43","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1002\/art.24936","article-title":"Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis.","volume":"60","author":"Bilgic","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"4","key":"doi220052r44","doi-asserted-by":"publisher","first-page":"657","DOI":"10.21873\/invivo","article-title":"Elevated IL-4 and IFN-? levels in muscle tissue of patients with dermatomyositis.","volume":"31","author":"Giris","year":"2017","journal-title":"In Vivo"},{"issue":"12","key":"doi220052r45","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1002\/art.34659","article-title":"Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course.","volume":"64","author":"Reed","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"3-4","key":"doi220052r46","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1159\/000452563","article-title":"MiR-146a regulates inflammatory infiltration by macrophages in polymyositis\/dermatomyositis by targeting TRAF6 and affecting IL-17\/ICAM-1 pathway.","volume":"40","author":"Yin","year":"2016","journal-title":"Cell Physiol Biochem"},{"issue":"9","key":"doi220052r47","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1016\/j.cellsig.2014.05.014","article-title":"Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.","volume":"26","author":"Schafer","year":"2014","journal-title":"Cell Signal"},{"issue":"6","key":"doi220052r48","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1136\/annrheumdis-2016-210189","article-title":"Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.","volume":"76","author":"Maier","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"doi220052r49","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20969261","article-title":"Shared development of targeted therapies among autoimmune and inflammatory diseases: a systematic repurposing analysis.","volume":"12","author":"Petitdemange","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"13","key":"doi220052r50","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1111\/bph.14667","article-title":"Inhibition of phosphodiesterase-4 attenuates murine ulcerative colitis through interference with mucosal immunity.","volume":"176","author":"Li","year":"2019","journal-title":"Br J Pharmacol"},{"issue":"1","key":"doi220052r51","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4049\/jimmunol.1401867","article-title":"Mechanisms of Jak\/STAT signaling in immunity and disease.","volume":"194","author":"Villarino","year":"2015","journal-title":"J Immunol"},{"issue":"6","key":"doi220052r52","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK-STAT pathway targeting for the treatment of inflammatory bowel disease.","volume":"17","author":"Salas","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"doi220052r53","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1080\/08998280.2020.1821589","article-title":"Refractory dermatomyositis-systemic lupus erythematosus overlap syndrome and response to tofacitinib.","volume":"34","author":"Williams","year":"2020","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"3","key":"doi220052r54","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/ddg.v19.3","article-title":"Treatment of refractory anti-NXP2 and anti-TIF1? dermatomyositis with tofacitinib.","volume":"19","author":"Navarro-Navarro","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"doi220052r55","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1093\/rheumatology\/key366","article-title":"Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib.","volume":"58","author":"Moghadam-Kia","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"doi220052r56","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/rheumatology\/keaa558","article-title":"Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review.","volume":"60","author":"Yu","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"doi220052r57","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1001\/jamadermatol.2016.0866","article-title":"Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment.","volume":"152","author":"Kurtzman","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"3","key":"doi220052r58","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.v31.3","article-title":"NanoString technology distinguishes anti-TIF-1?+ from anti-Mi-2+ dermatomyositis patients.","volume":"31","author":"Preusse","year":"2021","journal-title":"Brain Pathol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2796849\/jamadermatology_bitar_2022_oi_220052_1670609097.14083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T11:11:49Z","timestamp":1671621109000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2796849"}},"subtitle":["A Nonrandomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":58,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2022.3917","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,1]]}}}